 Susana Chavez-Bueno
Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Escherichia coli | 6 | 2023 | 28 | 3.590 |
Why?
| | Bacteremia | 5 | 2023 | 25 | 3.060 |
Why?
| | Escherichia coli Infections | 5 | 2023 | 19 | 2.270 |
Why?
| | Respiratory Syncytial Virus Infections | 15 | 2017 | 41 | 1.920 |
Why?
| | Anti-Bacterial Agents | 10 | 2021 | 244 | 1.670 |
Why?
| | Drug Resistance, Bacterial | 6 | 2021 | 14 | 1.430 |
Why?
| | Infant, Newborn | 9 | 2023 | 828 | 0.920 |
Why?
| | Pediatrics | 4 | 2010 | 175 | 0.910 |
Why?
| | Cervix Uteri | 1 | 2021 | 1 | 0.850 |
Why?
| | Obstetric Labor, Premature | 1 | 2021 | 1 | 0.850 |
Why?
| | Respiratory Syncytial Viruses | 8 | 2008 | 16 | 0.790 |
Why?
| | Humans | 25 | 2023 | 6797 | 0.730 |
Why?
| | Antibodies, Monoclonal | 7 | 2007 | 23 | 0.670 |
Why?
| | Respiratory Syncytial Virus, Human | 5 | 2017 | 23 | 0.660 |
Why?
| | Infant, Newborn, Diseases | 1 | 2017 | 34 | 0.610 |
Why?
| | Antiviral Agents | 6 | 2007 | 26 | 0.590 |
Why?
| | Pneumonia, Mycoplasma | 7 | 2006 | 15 | 0.470 |
Why?
| | Cell Line | 3 | 2023 | 80 | 0.450 |
Why?
| | Phylogeny | 3 | 2023 | 21 | 0.450 |
Why?
| | Female | 16 | 2021 | 3599 | 0.420 |
Why?
| | Lung | 11 | 2007 | 74 | 0.410 |
Why?
| | Genotype | 3 | 2019 | 401 | 0.410 |
Why?
| | Haptoglobins | 1 | 2011 | 1 | 0.400 |
Why?
| | Term Birth | 1 | 2011 | 1 | 0.400 |
Why?
| | Virulence | 3 | 2023 | 7 | 0.400 |
Why?
| | Cytokines | 12 | 2020 | 48 | 0.390 |
Why?
| | Ribavirin | 2 | 2007 | 2 | 0.390 |
Why?
| | Vaccines | 1 | 2010 | 17 | 0.380 |
Why?
| | Infant, Premature | 1 | 2011 | 85 | 0.370 |
Why?
| | Microbial Sensitivity Tests | 4 | 2021 | 32 | 0.360 |
Why?
| | Mycoplasma pneumoniae | 6 | 2006 | 12 | 0.360 |
Why?
| | Methicillin Resistance | 2 | 2007 | 3 | 0.350 |
Why?
| | Community-Acquired Infections | 2 | 2007 | 10 | 0.350 |
Why?
| | Staphylococcus aureus | 2 | 2007 | 19 | 0.340 |
Why?
| | Mice | 17 | 2020 | 312 | 0.340 |
Why?
| | Staphylococcal Infections | 2 | 2007 | 23 | 0.340 |
Why?
| | Animals | 18 | 2020 | 664 | 0.320 |
Why?
| | Immunocompromised Host | 1 | 2007 | 7 | 0.320 |
Why?
| | Multilocus Sequence Typing | 2 | 2019 | 3 | 0.300 |
Why?
| | Prospective Studies | 3 | 2021 | 522 | 0.300 |
Why?
| | United States | 4 | 2019 | 656 | 0.270 |
Why?
| | Clindamycin | 1 | 2005 | 3 | 0.270 |
Why?
| | Host-Pathogen Interactions | 1 | 2005 | 8 | 0.270 |
Why?
| | Child Welfare | 1 | 2005 | 6 | 0.270 |
Why?
| | Child | 10 | 2011 | 3257 | 0.260 |
Why?
| | Infant | 8 | 2017 | 1449 | 0.260 |
Why?
| | Airway Obstruction | 7 | 2005 | 13 | 0.260 |
Why?
| | Mice, Inbred BALB C | 12 | 2007 | 26 | 0.260 |
Why?
| | Genetic Predisposition to Disease | 1 | 2005 | 224 | 0.240 |
Why?
| | Escherichia coli Proteins | 1 | 2023 | 3 | 0.240 |
Why?
| | Transcytosis | 1 | 2023 | 1 | 0.230 |
Why?
| | Epithelium | 1 | 2023 | 6 | 0.230 |
Why?
| | Male | 8 | 2017 | 3328 | 0.220 |
Why?
| | Palivizumab | 6 | 2007 | 7 | 0.210 |
Why?
| | Genome, Bacterial | 1 | 2021 | 1 | 0.210 |
Why?
| | Epithelial Cells | 1 | 2021 | 3 | 0.210 |
Why?
| | Chemokines | 9 | 2007 | 11 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2007 | 31 | 0.210 |
Why?
| | Bronchoalveolar Lavage Fluid | 9 | 2007 | 12 | 0.200 |
Why?
| | Pilot Projects | 1 | 2021 | 128 | 0.200 |
Why?
| | Bronchial Hyperreactivity | 6 | 2008 | 6 | 0.200 |
Why?
| | Pneumonia | 3 | 2006 | 31 | 0.190 |
Why?
| | Pregnancy | 1 | 2021 | 271 | 0.190 |
Why?
| | Receptors, Interleukin-1 | 1 | 2020 | 9 | 0.180 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 12 | 0.180 |
Why?
| | Intestines | 1 | 2020 | 26 | 0.180 |
Why?
| | Bronchiolitis, Viral | 2 | 2017 | 4 | 0.180 |
Why?
| | Young Adult | 1 | 2021 | 665 | 0.170 |
Why?
| | Disease Models, Animal | 7 | 2008 | 74 | 0.170 |
Why?
| | Child, Preschool | 7 | 2011 | 1503 | 0.170 |
Why?
| | Adult | 2 | 2021 | 1259 | 0.170 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2020 | 71 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2007 | 41 | 0.150 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 89 | 0.140 |
Why?
| | Erythromycin | 2 | 2007 | 3 | 0.140 |
Why?
| | Ketolides | 2 | 2006 | 2 | 0.140 |
Why?
| | Clarithromycin | 2 | 2006 | 3 | 0.130 |
Why?
| | Risk Factors | 3 | 2005 | 470 | 0.130 |
Why?
| | Asthma | 3 | 2006 | 143 | 0.130 |
Why?
| | Respiratory Tract Infections | 2 | 2007 | 75 | 0.130 |
Why?
| | Inflammation | 3 | 2020 | 51 | 0.130 |
Why?
| | Treatment Outcome | 2 | 2007 | 667 | 0.120 |
Why?
| | Bacterial Capsules | 1 | 2014 | 1 | 0.120 |
Why?
| | Tobramycin | 1 | 2014 | 3 | 0.120 |
Why?
| | Bacterial Typing Techniques | 1 | 2014 | 4 | 0.120 |
Why?
| | Gentamicins | 1 | 2014 | 5 | 0.120 |
Why?
| | Antigens, Bacterial | 1 | 2014 | 9 | 0.120 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2014 | 10 | 0.120 |
Why?
| | Cells, Cultured | 1 | 2014 | 76 | 0.120 |
Why?
| | Adolescent | 4 | 2011 | 2137 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 23 | 0.120 |
Why?
| | Phenotype | 1 | 2014 | 244 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2017 | 144 | 0.110 |
Why?
| | Incidence | 2 | 2011 | 132 | 0.110 |
Why?
| | Biomarkers | 2 | 2011 | 123 | 0.110 |
Why?
| | Viral Load | 2 | 2017 | 20 | 0.110 |
Why?
| | RNA, Viral | 3 | 2008 | 16 | 0.100 |
Why?
| | Vancomycin | 1 | 2011 | 17 | 0.100 |
Why?
| | Overweight | 1 | 2011 | 48 | 0.100 |
Why?
| | Disease Susceptibility | 1 | 2011 | 12 | 0.100 |
Why?
| | Reference Values | 1 | 2011 | 41 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 34 | 0.100 |
Why?
| | Polymerase Chain Reaction | 3 | 2005 | 88 | 0.100 |
Why?
| | Respiratory Sounds | 2 | 2008 | 6 | 0.100 |
Why?
| | Obesity | 1 | 2011 | 135 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 147 | 0.090 |
Why?
| | Risk Assessment | 1 | 2011 | 137 | 0.090 |
Why?
| | Hospitals, Pediatric | 2 | 2011 | 183 | 0.090 |
Why?
| | Cohort Studies | 1 | 2011 | 274 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2011 | 327 | 0.090 |
Why?
| | Bacterial Proteins | 2 | 2007 | 8 | 0.090 |
Why?
| | Texas | 2 | 2007 | 17 | 0.090 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2005 | 3 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2007 | 14 | 0.080 |
Why?
| | Antibodies, Viral | 2 | 2007 | 46 | 0.080 |
Why?
| | Prognosis | 2 | 2005 | 213 | 0.080 |
Why?
| | Orthomyxoviridae | 1 | 2007 | 2 | 0.080 |
Why?
| | Weather | 1 | 2007 | 4 | 0.080 |
Why?
| | Interleukin-12 | 1 | 2006 | 3 | 0.070 |
Why?
| | Vaccines, Subunit | 1 | 2006 | 3 | 0.070 |
Why?
| | Vaccines, Attenuated | 1 | 2006 | 8 | 0.070 |
Why?
| | Influenza, Human | 1 | 2007 | 57 | 0.070 |
Why?
| | Bronchiolitis | 1 | 2006 | 11 | 0.070 |
Why?
| | Amidohydrolases | 1 | 2005 | 2 | 0.070 |
Why?
| | Peptides | 1 | 2005 | 9 | 0.070 |
Why?
| | Azithromycin | 1 | 2005 | 5 | 0.070 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2005 | 2 | 0.070 |
Why?
| | Primary Prevention | 1 | 2005 | 2 | 0.070 |
Why?
| | Pneumococcal Vaccines | 1 | 2005 | 4 | 0.070 |
Why?
| | Chemoprevention | 1 | 2005 | 4 | 0.070 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 7 | 0.070 |
Why?
| | Morbidity | 1 | 2005 | 11 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2005 | 4 | 0.070 |
Why?
| | Global Health | 1 | 2005 | 13 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 11 | 0.070 |
Why?
| | Plethysmography | 4 | 2006 | 5 | 0.070 |
Why?
| | Dexamethasone | 1 | 2005 | 30 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2005 | 82 | 0.070 |
Why?
| | Pneumonia, Viral | 1 | 2005 | 17 | 0.070 |
Why?
| | Patient Selection | 1 | 2005 | 42 | 0.070 |
Why?
| | Vaccination | 1 | 2005 | 68 | 0.070 |
Why?
| | Sequence Analysis, DNA | 1 | 2005 | 115 | 0.060 |
Why?
| | Respiratory Mechanics | 1 | 2004 | 2 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2005 | 97 | 0.060 |
Why?
| | Cephalosporins | 1 | 2004 | 16 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2004 | 6 | 0.060 |
Why?
| | Metapneumovirus | 1 | 2004 | 12 | 0.060 |
Why?
| | Paramyxoviridae Infections | 1 | 2004 | 12 | 0.060 |
Why?
| | Virulence Factors | 1 | 2023 | 5 | 0.060 |
Why?
| | Virus Replication | 3 | 2008 | 6 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 113 | 0.060 |
Why?
| | Time Factors | 3 | 2008 | 247 | 0.050 |
Why?
| | Adenosine Diphosphate Ribose | 1 | 2000 | 1 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 1 | 0.050 |
Why?
| | NAD | 1 | 2000 | 3 | 0.050 |
Why?
| | Kupffer Cells | 1 | 2020 | 3 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 7 | 0.050 |
Why?
| | Probiotics | 1 | 2020 | 8 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2020 | 20 | 0.050 |
Why?
| | Infant Formula | 1 | 2020 | 15 | 0.050 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 9 | 0.050 |
Why?
| | Ileum | 1 | 2020 | 18 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2020 | 53 | 0.050 |
Why?
| | Apoptosis | 1 | 2020 | 51 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2020 | 36 | 0.050 |
Why?
| | Signal Transduction | 1 | 2020 | 111 | 0.040 |
Why?
| | Interferons | 1 | 2017 | 1 | 0.040 |
Why?
| | Neutrophils | 1 | 2017 | 11 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2017 | 21 | 0.040 |
Why?
| | Nasopharynx | 1 | 2017 | 25 | 0.040 |
Why?
| | Chronic Disease | 2 | 2008 | 104 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 95 | 0.040 |
Why?
| | Length of Stay | 1 | 2017 | 243 | 0.040 |
Why?
| | Genetic Variation | 1 | 2017 | 167 | 0.040 |
Why?
| | Hospitalization | 1 | 2017 | 194 | 0.030 |
Why?
| | Plethysmography, Whole Body | 2 | 2004 | 2 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 27 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 41 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2011 | 75 | 0.030 |
Why?
| | Logistic Models | 1 | 2011 | 93 | 0.030 |
Why?
| | Viral Plaque Assay | 1 | 2007 | 1 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2007 | 1 | 0.020 |
Why?
| | Exotoxins | 1 | 2007 | 1 | 0.020 |
Why?
| | Leukocidins | 1 | 2007 | 1 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2007 | 5 | 0.020 |
Why?
| | Granzymes | 1 | 2007 | 1 | 0.020 |
Why?
| | Caspase 3 | 1 | 2007 | 6 | 0.020 |
Why?
| | Meteorological Concepts | 1 | 2007 | 3 | 0.020 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 5 | 0.020 |
Why?
| | Temperature | 1 | 2007 | 10 | 0.020 |
Why?
| | Humidity | 1 | 2007 | 3 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 9 | 0.020 |
Why?
| | Bodily Secretions | 1 | 2007 | 3 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2007 | 7 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2007 | 12 | 0.020 |
Why?
| | Prevalence | 1 | 2007 | 149 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2007 | 30 | 0.020 |
Why?
| | Placebos | 1 | 2006 | 6 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2006 | 58 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2006 | 49 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2011 | 1332 | 0.020 |
Why?
| | Acute Disease | 1 | 2006 | 71 | 0.020 |
Why?
| | Recurrence | 1 | 2006 | 123 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2005 | 9 | 0.020 |
Why?
| | Infant, Premature, Diseases | 1 | 2005 | 23 | 0.020 |
Why?
| | Lung Diseases, Obstructive | 1 | 2004 | 3 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 44 | 0.020 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2004 | 1 | 0.020 |
Why?
| | Tissue Fixation | 1 | 2004 | 2 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2004 | 4 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 20 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 16 | 0.020 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2004 | 2 | 0.020 |
Why?
| | Sex Distribution | 1 | 2004 | 18 | 0.020 |
Why?
| | Education, Medical, Continuing | 1 | 2004 | 6 | 0.020 |
Why?
| | Age Distribution | 1 | 2004 | 32 | 0.020 |
Why?
| | Polymers | 1 | 2000 | 3 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 9 | 0.010 |
Why?
| | Hydrolysis | 1 | 2000 | 3 | 0.010 |
Why?
| | Glutamic Acid | 1 | 2000 | 3 | 0.010 |
Why?
| | Thymus Gland | 1 | 2000 | 3 | 0.010 |
Why?
| | Cattle | 1 | 2000 | 25 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|